Buzz Grows Around Biotech At Former AstraZeneca Campus
Executive Summary
Chris Doherty, managing director of the UK's Alderley Park, tells Scrip that the departure of the drug giant from its global R&D headquarters has acted as a catalyst to create a vibrant biotech cluster that is attractive to local, national and international companies.
You may also be interested in...
Redx Ready To Get Back To The Clinic After Tough Year
CEO Lisa Anson has brought "a sense of urgency, focus and realism" to Redx since she took over five months ago, says its chairman, and the firm has high hopes for its investigational porcupine inhibitors.
Manchester United With Big Pharma On Improving Outcomes
The English city's desire to collaborate with the pharmaceutical industry to come up with cost-effective solutions to treat long-term chronic diseases has seen Manchester emerge as a closely watched experiment for the future of health care.
Redx Rises Out Of Administration With R&D Refocus
After a tough summer, the UK firm has exited insolvency with new management and programs in cancer and fibrosis, having decided to shut down its anti-infectives business.
Need a specific report? 1000+ reports available
Buy Reports